Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lanie K. Francis
Observed name:
Lanie Francis
Institutions:
University of Southern California,
Children's Hospital of Los Angeles,
USC Norris Comprehensive Cancer Center
Observed institutions:
University of Southern California,
Children's Hospital of Los Angeles,
University of Pittsburgh,
USC Norris Comprehensive Cancer Center,
UPMC Hillman Cancer Center,
University of Pittsburgh Medical Center
show all 6
OpenAlex ID:
A5014853652
The accuracy of predicting survival in individual patients with cancer
2013
·
Douglas Kondziolka
, Phillip V. Parry
, et al.
·
Journal of neurosurgery
·
134
Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma
2006
·
Lanie K. Francis
, Yazan Alsayed
, et al.
·
Clinical Cancer Research
·
91
PDF
Developing national cancer survivorship standards to inform quality of care in the United States using a consensus approach
2024
·
Michelle A. Mollica
, Gina McWhirter
, et al.
·
Journal of Cancer Survivorship
·
80
Fortifying the Treatment of Prostate Cancer with Physical Activity
2016
·
Colin E. Champ
, Lanie Francis
, et al.
·
Prostate Cancer
·
22
PDF
Learning to Listen: A Fellow's Experience
2006
·
Lanie K. Francis
·
Journal of Clinical Oncology
·
6
PDF
Combination of the AKT Inhibitor Perifosine with the HSP90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin (17-DMAG) Has Synergistic Activity in Multiple Myeloma (MM).
2005
·
Alissa Huston
, Lanie Francis
, et al.
·
Blood
·
3
The Role of the AKT Inhibitor Perifosine in Migration and Adhesion in Multiple Myeloma (MM).
2005
·
Alissa Huston
, Ujjal Singha
, et al.
·
Blood
·
2
A Post-Modern View of Women in Hematology: A Focus on Work/Life Balance
2012
·
Lanie Francis
·
The Hematologist
·
1
Women in Hematology — Where Are We today?
2007
·
Lanie Francis
·
The Hematologist
·
1
Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative Disorders (PTLD).
2005
·
Yazan Alsayed
, Ujjal Singha
, et al.
·
Blood
·
1
The Role of the CXCR4 Inhibitor AMD3100 in Multiple Myeloma (MM).
2005
·
Irene M. Ghobrial
, Mona Melhem
, et al.
·
Blood
·
1
Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) Using Nanoscale Protein Micorarray Techniques.
2005
·
Yazan Alsayed
, Michael Timm
, et al.
·
Blood
·
1
The Effect of Rapamycin, 17-AAG and the Combination on the Bone Marrow Microenvironment in Multiple Myeloma (MM).
2005
·
Lanie Francis
, Judy Anderson
, et al.
·
Blood
·
1
Development of an Oncologist-Driven Integrative Intervention for Symptom Management in an Academic Cancer Center
2018
·
Lanie K. Francis
, Mia P. Weiss
, et al.
·
Journal of Oncology Practice
PDF
Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD).
2005
·
Yazan Alsayed
, Ujjal Singha
, et al.
·
Blood
Proteomic Analysis Identifies Differences in Multiple Myeloma (MM) Cells Sensitive and Resistant to AKT Inhibition.
2005
·
Alissa Huston
, Alexey Leontovich
, et al.
·
Blood
Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia.
2005
·
Irene M. Ghobrial
, Mona Melhem
, et al.
·
Blood
Proteomic Analysis of Post Transplant Lymphoproliferative Disorders (PTLD) Using Nanoscale Protein Microarray Techniques.
2005
·
Yazan Alsayed
, Alexey Leontovich
, et al.
·
Blood
Molecular Mechanisms Regulating Migration and Adhesion in Response to the Chemokine SDF-1 in Multiple Myeloma (MM).
2005
·
Irene Ghobrial
, Ujjal Singha
, et al.
·
Blood
My First American Society of Clinical Oncology Annual Meeting: Inspiration, Education, and Perspective
2005
·
Lanie K. Francis
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
20
Citation count:
344
H-index:
5
I10-index:
4
Year
Topic
Type
